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Abstract
To further substantiate the role of inter-organizational networking in innovation, we 
explored the positive impact of large networks on innovation in the biotechnology 
industry. The research was conducted in two parts. In the first part, a qualitative 
research methodology using exploratory case study is performed on the three SME 
members of the UK-based biotech network One Nucleus. In the second part, a 
quantitative research approach using comparative empirical OECD data analysis 
is performed. The two research methodologies used are subsequently linked together 
thorough a unique research approach known as processual research. A new insight 
is explored regarding issues linked to inter-organizational networking, like the role 
of networks on organizational learning, the role of third party organizations within 
networks, diversity of partners and the nature of learning (localized vs. global) within 
biotech networks. The primary data is generated on the number of alliances, types 
of alliances and types of innovation, whereas innovation is measured as a dependent 
variable. Empirical results obtained clearly indicate that innovation output (patent 
approval rate, patent success rate) with respect to each alliance made by the sample 
firms is positively impacted by the parent biotech network One Nucleus.
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INTRODUCTION
Biotechnology is a multi-billion global industry; it encompasses several sectors or fields of applications, with several different research technologies or innovations. Innovation is indispensable for 
economic growth (Schumpter, 1934); therefore, it is not surprising that in 
highly technology-based industries like biotechnology, innovation is regarded 
as a mantra of success. Biotechnology has revolutionized the conventional 
knowledge of the pharmaceutical industry with new discoveries in novel areas 
like drug delivery, molecular genetics, immunology and cell biology (Gans and 
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of the biotech industry is both complex and expanding; rather than capitalizing 
on the success of individual firm, the locus of innovation will be found in inter-
organizational networks. Innovation is widely accepted as a collective process 
in which rapid technological changes and inter-organizational networking play 
an important central role (Smith and Powell, 2004).  A substantial amount of 
theoretical and empirical research on the role of networking has been done in 
the last two decades. Networking, either external or internal, creates a tacit 
flow of knowledge, which is vital for innovation. The knowledge shared by 
either informal or formal communication between collaborating firms leads 
to collective invention, which fosters innovation (Allen, 1983). To sustain 
innovation firms has to rely more on external collaboration, the boundaries of 
the firm get faint as firms become integrated within large networks and assume 
a central role within these networks and uses continuous knowledge flow to 
sustain their innovation processes (Smith and Powell, 2004).
Despite a continuous flow of innovation, newly developed biotech firms 
generally find it difficult to sustain the innovation process in early phase of 
their industry life cycle. (Accenture and Babson College, 2004). Baker’s 
(2003) research shows that Biotech companies face organizational challenges 
in sustaining their innovation process as their products move down the pipeline. 
The integration of biotech firms with large biotech networks overcomes 
organizational challenges and helps firms to form formal or informal alliances, 
which foster innovation. Inter-firm networking has its advantages as well as 
its disadvantages. The sharing of knowledge and ideas within different firms 
increases the competence of firms; on the other hand, networking does not 
always prove beneficial. Sometimes networking makes it difficult for the firms 
to achieve innovativeness and desired profitability (Ozman, 2009).
Chin (2004) underlined the importance of field-based medical science 
liaisons. Co-operation and exchange of information between different 
organizations is considered an important special force in biotech innovation. 
Garcia and Velasco (2005) studied the effect of cooperation networks and 
geographic clustering on innovation performance. They argued that the critical 
resources, such as technological knowledge spillover, downstream competence 
of product development and finance, may represent micro mechanisms for the 
improvement of the innovation capability of the biotech firm.
The knowledge spillovers generally resulted from informal communication 
among biotech companies and could lead to collective invention of ideas, 
products and processes (Allen, 1983). Inter-organizational networking 
generally depends on the type of industry: Each specific industry setting 
influences the shape of the network structure (Kogut, 2000). The emergence 
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technology (Soh and Roberts, 2003). A closer look at the available literature 
describes the network of firms in various ways. Granovetter (1998) explained 
networking in business groups, where firms are bound together in the form of 
informal and formal relationships. This type of relationship is neither strong, 
because firms in business groups are generally consolidated into a legal 
single entity, nor is this relationship weak, as firms benefit from short-term 
strategic alliances. The locus of innovation is embedded in the network of 
inter-organizational learning and the creation of knowledge-sharing networks 
for sustained business practices among highly technological firms (Powell, 
Koput and Smith-Doerr, 1996). Ring and Van DeVen (1994) and Oliver (1990) 
explained the inter-organizational relationships for cooperation and sharing of 
tacit knowledge among technological firms. DeBresson and Amesse (1991) 
described inter-organizational networking as a linking of innovators in strategic 
inter-firm network partnerships.
In our research paper, we presented an in-depth investigation of the role 
of large networks in fostering innovation. The qualitative research approach 
applied in this paper involved open-ended exploratory telephone interviews 
for primary data collection and a case study analysis of three sample firm 
members of the biotech network One Nucleus. The quantitative approach was 
utilised in the empirical analysis of country-specific OECD (Organization for 
Economic Co-operation and Developement) indicators in the biotech industry. 
Our research aims to bridge the gap in the literature, where the primary focus 
is on the impact of networking on product innovation and largely ignores the 
relationship between process and organizational innovation. The network 
innovation research is also relevant because it explores the changing dynamics 
and configurations of inter-organizational networking. The findings of this 
paper can be useful for future researchers who aim to study the industry in 
different period of time. Moreover, this research provides fresh insight into the 
issues linked to inter-organizational networking. New insight is obtained on 
the important aspects of networking, such as organizational learning, diversity 
of partners, the role of third party organizations in collaboration, the types 
of alliances and the nature of learning for sample biotech firms in the large 
biotech network ‘One Nucleus’. The overall relevance of this research paper 
is to substantiate the fact that the innovation output of three sample firms 
(AERES Biomedical Ltd., AnGes Inc. and Polytherics Ltd.) is positively 
impacted by a number of alliances with organizations within and outside the 
biotech network One Nucleus. The network One Nucleus was formed in April 
2001 by the merger of two life science networks, the London-based London 
biotechnology network (BioLondon) and Cambridge-based ERBI. The merger 
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which resulted in several benefits for member firms, research centres and 
Universities, like support for business-to-business interaction, enhanced 
competitiveness at the global and local levels (through  shared organizational 
learning and knowledge transfer) and fostering of innovation.
LITERATURE REVIEW
Early innovation theories of the 1950s and 1960s considered R&D the 
primary source of innovation. These theories considered a firm’s technological 
knowledge to be its core competence in sustaining growth and profit and 
largely ignored external market forces (Lippitt, Watson, and Westly, 1958). A 
later theory by Clark (1979) contradicted this notion and considered market 
forces the primary driver of innovation, assigning R&D a merely secondary 
role. With globalization, the complexities of international business became 
apparent. In the globalized world of inter-connectedness, where the benefits 
and gains of one country are dependent on the benefits and gains of other 
country, firms struggled to sustain their innovation models. Therefore, new 
theories of integrated organizational approach gained wide attention, and 
the need for a new integrative theoretical model led to the emergence of 
growing network research. New theoretical innovation models highlighted the 
importance of inter-organizational networks, where innovation is accepted as 
a collective process (Edwards, 2000; Johnson et al., 2001; Meyer and Mugge, 
2001). This assumption sounds good, if we consider the strategic options of 
global firms, which are focusing on building inter-firm networks to sustain 
their innovativeness, profitability and performance. In the last decade, global 
firms have been involved in building network of relationships, which is evident 
from increased merger and acquisitions activities, R&D alliances, franchising, 
licensing or other types of know-how trading interactions at a local or a global 
level (Ozman, 2009).
Why Firms Collaborate? 
Oliver (1990), in his pioneering research paper, thoroughly explained the 
motives and reasons behind the collaborations. Organizations are motivated 
to form collaborations for the following reasons: (1) urgency within the firms 
to meet regulatory or legal requirements; (2) exploring the opportunities to 
control another organization; (3) exploring the opportunities of collaboration 
rather than control (horizontal linkages preferred over vertical); (4) efforts of 
the organization to enhance its competence and to increase its internal input-
output ratio; (5) response to economic uncertainty by gaining stability; and 
(6) gaining legitimacy by improving prestige, image and reputation. Existing 




Journal of Technology Management for Growing Economies, Volume 3, Number 2, October 2012
the importance of the reasons discussed above. For example, in the case of 
biotechnology, joint ventures are the main objective behind collaboration. 
They overcome the effect of asymmetry and ultimately, larger firms exercise 
organizational control over smaller firms (Kogut, 1988). 
Resource Interdependence 
The resource-based approach proposed by Wernfelt (1984) is the most wide-
spread and earliest approach that explains why firms collaborate. According 
to this view, firms collaborate to gain interdependence in resource utilization. 
This view is much in accordance with the findings of Pfeffer and Salancik 
(1978), and later Hagedoorn (1993) justified this view. The resource-based ap-
proach motivates those firms that are not self-sufficient to form alliances with 
other firms to gain access to each other’s resources. The overall repercussion 
of collaboration is that it reduces uncertainty within the technologically inten-
sive firms and makes them self-sufficient in the optimal utilization of resourc-
es. In the biotech industry, the main factor that motivates companies to form 
inter-organizational relationships is the multidisciplinary character and com-
plexity of the knowledge base (Hagedoorn, 1993). The large and established 
pharmaceutical companies mostly prefer strategic alliances, as this gives them 
an opportunity to access the markets and knowledge bases of small firms (Aro-
ra and Gambardella, 1990; Shan, Walker, and Kogut, 1994; Walker, Kogut, 
and Shan, 1997). Arora and Gambardella (1994) researched the findings for 
the biotech industry and found that a firm’s technological capability increases 
the number of collaborative agreements, while scientific capability reduces 
their number. This resource-based view supports the most pragmatic thinking 
behind the fostering of innovation due inter-organizational networking. The 
creation of inter-organizational clusters brings technological firms, investors, 
specialized suppliers, universities and schools together to form a densely con-
nected critical mass, where social capital is expressed to generate a knowledge 
flow (Prahalad and Mashelkar, 2010).
Organizational Learning 
The pioneering research paper that explained the role of inter-organizational 
networking in the creation of innovation in biotech industry is by Powell, 
Koput, and Smith-Doerr (1996). Their research placed the concept of 
organizational learning at the epicentre of the network literature. According to 
their research, alliance formation leads to the vital process of organizational 
learning. The technological firms collaborate not only to access resources of 
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to the process of organizational learning. Thus, organizational learning is 
both a function of creating new capabilities for exploiting tacit knowledge 
and creating organizational channels to access such knowledge (Powell, 
Koput, and Smith-Doerr, 1996). The expansion and exploitation of existing 
knowledge is largely complemented by external collaborations, which directly 
build internal capabilities within organization to effectively explore the 
possibilities of business from new knowledge (Mowery, 1989). Collaboration 
not only strengthens internal competencies but also enhances organizational 
learning about new technological developments; thus, the locus of innovation 
is embedded in the inter-organizational networks of learning (Powell, Koput, 
and Smith-Doerr, 1996). Oliver (2001) studied the exploitation and exploration 
alliances in the context of the life cycle of the firm. The external conditions like 
the growth phases of the firms or the stages in industry life largely motivate 
firms to collaborate. Lavie and Rosenkopf (2006) investigated the role of 
absorptive capacity and organizational inertia within firms in balancing the 
exploitation and exploration alliances. As pointed out earlier, collaborations 
are not always useful because there are indeed negative consequences of 
knowledge transfer. The type of partnership is related to the innovativeness of 
the firm: Firms that are technologically more innovative usually restrain the 
transfer of tacit knowledge by forming a diverse range of partnerships (Dutta 
and Weiss, 1997). Oxley and Sampson (2004) studied the negative impact of 
unintended leakage in vital technologies, which hamper R&D alliances and 
force firms to become competitors rather partners. This perceived anomaly 
in alliance, especially in communications and electronic equipment firms, 
is generally overcome by limiting the scope of alliances and by regulating 
the flow of knowledge. This dual character of organizational learning was 
researched by Mohr and Sengupta (2002); their research investigated the 
negative impact of unintended transfer of knowledge on collaboration and the 
long-term innovation process. 
External factors
Other factors like external uncertainty, size of the firm, life cycle of firm and 
industry, type of alliance and firm social ties influences firm’s performance, 
capabilities and innovativeness. Gulati and Higgins (2003) examined the 
case of young biotechnology firm and its IPO performance, their work shows 
that linkage benefits of investment bank and venture capital depends on the 
growth phase of the firm or the stage in the industry life cycle. Studies by 
Beckman and Haunschild (2004) examine the motivation for exploitation 
versus exploration alliances in the context of industry life cycle, life cycle of 
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that external conditions like life cycle of the industry and life cycle of the firm 
forces firms to collaborate. 
Diversity of Partners
Dutta and Weiss (1997) examined the relationship between the innovativeness 
of the firm and the type of partnership involved. Their study highlighted 
the importance of diversity in the partner selection choice exercised by the 
firm; the more diverse the partner is, the greater the ease of regulating and 
restraining the flow of tacit knowledge. Studies carried out by Baum et al. 
(2000) show that when start-up biotech firms form networks of relationship 
with different organizations like universities, research institutes and other 
firms, their performance increases. The added competencies of diverse partners 
are very helpful in generating radical innovations. However, studies carried out 
by Goerzen and Beamish (2005) show the negative impact of partner diversity: 
in the case of multinational firms, the large partner diversity creates conflicts 
between partners and lowers the multinational firms’ performance. 
Effect of geographical proximity
Geographical proximity plays an important role in the diffusion of innovation. 
Studies carried out by Aharonson et al. (2004) validate this point, and a case 
study on biotech firms shows that clustered firms have face-to-face contacts 
and are in the central position of their knowledge network, which increases 
their innovativeness. The evolutionary view of innovation considers the firm as 
a central force in shaping the regional innovation performance. This localized 
nature of learning within a fixed geographical region fosters innovation and 
a firm’s performance (Capello, 1999). Geographical proximity allows firms 
to facilitate the diffusion of innovation (Porter, 1990). The latest research 
by Whittington and Smith (2009) further substantiated previous findings. 
Their study explains that the importance of external agencies, geographic 
propinquity and external network position enhances patenting activities and 
organizational innovation. The proximity of a biotech firm to external public 
sector knowledge centres such as universities and research institutes stabilizes 
its regional and global networking. Geographical proximity between inventors 
is mostly relevant in a situation of knowledge exploration, when knowledge is 
predominantly tacit (Anne and Wal, 2011). After discussing the issues linked 
to inter-organizational networking, we propose our first hypothesis.
Hypothesis 1: Inter-organizational alliances within large biotech networks 
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resource interdependence, organizational learning, diversity of partners, type 
of alliances and nature of learning (localized vs. global). 
Product and process innovation 
Commercializing and developing a new product involves large R&D costs. 
To cut these costs, biotech firms often collaborate with universities, research 
centres and R&D labs. Research done by George, Zahra and Wood (2001) 
shows that biotech companies that are not members of large biotech clusters 
often have large R&D budgets but low innovation output. They analyzed 2457 
alliances undertaken by 147 biotechnology firms, and the research results 
show large patent filing activities in these sample firms, with high innovation 
output. In technology-intensive industries, process innovation generates 
product innovation; therefore, product and process innovation systems are 
inter-related and their interaction is explained by a system dynamic approach 
(Milling and Stumpfe, 2000).  The biotech firm’s competencies are determined 
by its ability to foster innovation in its product portfolios. A product life cycle 
is generally short, and it becomes essential for biotech firms to enhance their 
process innovation capacity to generate more innovative products (Psiano, 
1997). The available scientific literature focused either on product innovation 
or on process innovation, without clearly considering the interaction between 
them. The process innovation in the biotechnology industry has an incremental 
impact on overall product innovation. The fundamental idea of this concept has 
been widely explored by previous researchers, and their findings are currently 
available in innovation literature (Butler, 1988; Ettlie, 1995; Damanpour and 
Gopalakrishnan, 1999). After discussing the impact of network on product and 
process innovation, we propose following hypotheses:
Hypothesis 2: Inter-organizational alliances positively impact the overall in-
novation output of biotech firms.   
Hypothesis 3: Large biotech networks positively impact the innovation out-
put of their member firms because the networks allow member firms to form 
different types of inter-organizational alliances based on their requirements.
METHODS AND DATA 
In this research, both qualitative and quantitative methods are used. Both 
research methods are appropriate to address the main research questions. 
The qualitative processual research (Orton, 1997; Pettigrew, 1997) method is 
used mainly to gain new insights from sample biotech firms on the different 
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analysis research method (Wolf, 1986) is used to empirically prove the positive 
impact of inter-organizational alliances on the overall innovation output of 
the sample firms, members of the biotech network One Nucleus. Using both 
research methodologies provides enough reliability to the final outcome of this 
research. Both research methodologies are bridged together by using a specific 
interpretive method known as processual research (Hinings, 1997; Orton, 
1997) and validated by the quantitative meta-analysis research method (Wolf, 
1986). Organizational phenomena such as inter-organizational networking is 
best studied through processual research. The methods of inductive grounded 
theory (Strauss and Corbin, 1990) shaped the methods of processual research. 
Like inductive grounded theory, processual research obtains data inductively 
and contextualizes it to generate an initial theory. Inductive organizational 
studies, which are “data rich, theory poor”, are researched by using processual 
research (Orton, 1997). The primary data generated through semi-structured 
in-depth interviews (inductive research method) and the secondary data 
acquired from reliable valid data resources (deductive research method) are 
interpreted to generate insights and theory without conflict or the notion that 
two methods of opposite orientations are used. Orton (1997) supported the 
use of processual research in iterative grounded theory. Fox-Wolfgramm 
(1997) used this theory for comparative case analysis. Though processual 
research alone limits the reliability of the method, it is complemented with 
the meta-analysis quantitative method of research (Wolf, 1986). The statistical 
procedures are applied to collect empirical findings from individual studies for 
final integration and synthesis of valid results in the meta-analysis research 
method. 
Qualitative Research Methodology 
To gain new insight on the important issues of inter-organizational networking, 
interpretive qualitative research methodology is followed because it provides 
a holistic view of wide organizational issues. Since this part of our research 
is primarily a case study research, the pure qualitative approach developed by 
Patton (1990) is adopted. Semi- structured interviews with respondents from 
three sample firms are conducted and their views are recorded on a number 
of core issues linked to inter-organizational networking, like resource-based 
view, organizational learning, types of innovation (product and process), the 
importance of diversity of partners, the role of third parties in collaboration, 
types of alliances and the nature of learning (localized vs. global).
We conducted the exploratory study on the impact of inter-organizational 
networking on innovation in London for three reasons. First, London is one of 
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capitalists and specialized services. Second, London is home to successful 
biotech firms, Small and medium sized enterprises (SME’s), large pharma 
companies, universities, medical schools, facility incubators, etc., hospitals, 
research institutes, government agencies and other business funding agencies. 
Third, all these organizations are part of the London biotechnology network 
now known as One Nucleus. The interview format selected is open-ended in-
depth semi-structured interviews. The selected themes of this research were 
explored by using this type of interview format because it could be easily 
directed toward the chosen theme. The open-ended research approach left the 
respondents free to express their views openly. Moreover, this format allows 
us to explore the organizational and other contextual issues that cannot be 
explored by using questionnaire surveys. For primary research purposes, we 
contacted 17 Biotech SMEs (members of the One Nucleus biotech network) 
to arrange face-to face-or telephonic interviews to carry out an open-ended 
exploratory study. Out of 17, only three companies gave permission. Therefore, 
the samples for primary research are three SMEs: 
(1)    AERES Biomedical Ltd. 
(2)    AnGes Inc. 
(3)    Polytherics Ltd.
Three interviewees, ABC, XYZ and DEF (names were kept anonymous due 
to pre-interview agreements of anonymity), from three sample SMEs, were 
contacted by e-mail to arrange face-to-face or telephonic interviews to carry 
out an open-ended exploratory study. Conducting telephone interviews has a 
great advantage, as it is the most economical way due to its low cost. They also 
tend to be conducted faster. In terms of questions, all but the most complex 
kinds can be asked over the telephone. Respondents were asked to share their 
views on the role of large biotech networks, inter-organizational alliances 
for the development of biotech, the role of third parties in alliances, the 
importance of diversity among partners, the nature of learning, the influence 
of collaborating firms, and the types of ties and embeddedness of firms within 
the network. The questions most asked of respondents were: (1) Why did your 
firm collaborate with other organizations within and outside the One Nucleus 
group? (2) What were the roles of third party firms/organizations in your 
partnership agreements? (3) What kind of partnership agreements does your 
firm hold with other firms/organizations? (4) How diverse are your partners? 
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(6) How has the geographic location of your partner organization influenced 
your firm’s overall innovation output? The respondents’ views gave us a clear 
view of their firms on the issues of collaboration, organizational learning, 
social connection and embeddedness. The respondents also shared their 
views on the issues of influence and imitation, diversity of partners, social 
connection (strong ties), structural holes (weak ties), and the nature of 
learning (localized vs. global). A special emphasis was to collect primary 
information on the number of alliances, number of patent applications 
filled, number of approved patents and number of successful patents. Since 
this research is “data rich, theory poor”, the primary data generated from 
interviews was validated by tracking the source of news and press releases 
of each sample firm. Important technical information collected was validated 
by obtaining online access to each sample firm’s databases, which contain 
all relevant information on alliances, patented technologies and products. 
The theoretical information collected on issues linked to inter-organizational 
alliances was also validated by triangulation. Data triangulation validates 
primary data with data generated from reliable data sources like press releases 
and firms’ internal login portals. The respondents’ responses were recorded 
using a portable audio device. Since the interviews were semi-structured, the 
main categories for the study analysis (e.g., type of innovation, role of third 
party, diversity of partners, types of alliances, number of alliances) were 
predetermined. Raw data were sorted out under separate headings for an 
effective analysis (Perreault and Leigh, 1989). The primary data collected on 
the number of alliances and type of alliances were tabulated separately in a 
table. A special coding scheme was developed to sort out the numbers of each 
type of alliance. This paper assumes partner biotech firms that are involved 
in R&D and commercialization as common entities under the heading of 
Business and R&D organization and gives them score of 1 each. Research 
institutes and universities that are involved in pure research are considered 
as common separate entities under the heading of Knowledge centre 
organizations and are scored as 1 each, also. Similarly, venture capitalists 
and funding organizations are considered as common separate entities under 
the heading of funding organizations and are scored as 1 each; in the same 
way, regulatory and legal firms are considered as common entities under the 
heading Legal organization and are scored as 1. Types of alliances are coded 
with abbreviations, e.g., licensing agreement as LA, research agreement as 
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The primary data on the number of alliances and types of collaboration 
agreements of each sample firm are recorded in tables, whereas the emerging 
point of view of interviewees on the core issues linked to inter-organizational 
networking were theoretically conceptualized into key propositions. These 
propositions are the key findings of this open-ended exploratory qualitative 
research. The processual research allows research questions to undergo 
variation because data analysis itself shapes the research design in advance, 
and the researcher might not be asking difficult questions (Fox-Wolfgramm, 
1997, p. 432). In this research, the viewpoint of respondents is very much 
biased on the different issues of networking. These wide discrepancies led to 
limited findings, with only two key propositions that can be said to be valid 
for the whole industry settings. The small sample size and time and money 
constriction restricted our efforts to contact sample firms more than once, 
thus limiting the reliability. 
Research findings and Data Analysis
This part of our research mainly focus on analysis of qualitative data through 
detailed descriptions of the sample firms’ views on a variety of issues linked 
to inter-organizational networking. The analysis is presented in a systematic 
pattern according to the real findings in complex behavioural settings. The 
key findings are then conceptualized as key propositions, whereas primary 
data related to each sample firm are compiled and presented in tabulated 
format. 
Sample Firm 1: AERES Biomedical Limited 
The company is part of the One Nucleus network. On telephonic interview, 
the company’s former CEO (name is kept anonymous due to company’s 
code of compliance in sharing information with outside network individuals/
organizations) shared his views on the broad issues of networking. The 
main reason explained by the AERES former CEO (currently holding an 
important position within the company) for having collaboration with 
other firms within and outside the One Nucleus group is to share the firm’s 
clinically proven technology of antibody humanization to commercially 
develop therapeutic antibodies for debilitating and life-threatening diseases. 
This response highlighted the importance of the resource-based view of 
networking discussed in the literature review. Research findings indicate 
the effective role of the parent network One Nucleus in providing desired 
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innovations with product innovation by allowing them to form collaborative 
agreements with desired partners. The most surprising issue that emerged 
from the telephonic interview was the company’s unwillingness to form 
new agreements on behalf of third party collaborators. This response points 
suggests a weak social connection and partial embeddedness of AERES within 
its network, which could limit the firm’s profitability and innovativeness in the 
long run, but to prove this assumption more detailed research is required, which 
is beyond the scope of this research paper. AERES Biomedical Limited has an 
average diversity in its partners, as most of its partners are small or medium-
sized biotech firms. Most of the alliances of AERES Biomedical Limited with 
its partners (Business, R&D) are for co-development of new products. The 
company had 32 collaborative alliances.
Primary data obtained for AERES Biomedical on number and types of 
alliances are given in table 1.
Table 1: Primary data obtained for AERES biomedical on number of alli-





R&D org (Avg 
score=1)
Partner Knowl-








1)  Acorda Therapeutics (USA)
2)  Antisoma (UK)
3)  Biotest Pharma (Germany
4)  Peregrine Pharma (US)
5)  National Cancer   Institute  (USA)
6)  Syngenta Biopharma (Switzerland)
7)  Lpath therapeutics (USA)
8)  Greenovation biotech (Germany)
9)  GENOVAC. (Germany)
1) National Cancer 
Institute (USA)
2)MRC Laborato-








Total major alliances =9
Other alliances=20, total=12+20= 32        
+2 +1 = 12
=32
Table 1 Data obtained from AERES Biomedical Ltd office by electronically. 
Note: most of the alliances of AERES biomedical limited with its partner (Busi-
ness, R&D) are for co-development of new products.
Sample firm 2: AnGes Inc.
AnGes Inc. is also a knowledge-based company and a part of One Nucleus 
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drugs by closely cooperating with pharmaceutical companies. According 
to the respondent, the company is collaborating mainly to take its drug 
development projects, which are in different stages, to another level. The 
respondent reveals that the network provides access for prospective partners 
in different product development stages, especially in application research 
and preclinical and clinical phases (i, ii, iii). The company is generating 
much of its revenue from royalties on its patented products. The licensing 
agreements, developmental assistance, initial contracts and principal 
payments have kept the company alive in sustaining its profitability and 
innovation model; thus, the company has both product and process innovations 
at its core. The respondent revealed that collaborations sometimes are not 
sustainable, as collaborating organizations sometimes breach the obligations 
under the agreement. The respondent revealed that AnGes Inc. had to 
terminate its licensing agreement with Transcription Factor Therapeutics 
Ltd. due to breaching of agreement by the firm. The respondent confirmed 
three methods of collaboration for sustaining innovation. This view of the 
respondent echoed the firm’s ongoing collaboration with industry, academia 
and government. This information shared by the respondent clearly shows 
the diversity in its partners, strong ties (rich social capital) and strong 
embeddedness of the firm in its organizational network. The respondent was 
clueless on the role of third party collaboration; instead, he pointed out direct 
alliances that the company holds with its partners. The most surprising fact 
that emerged from this interview was that the company identifies its Japan-
based collaboration as quite fruitful in generating radical innovation; this 
view of the respondent is evident from the successful generation of patents 
by AnGes Inc. in Japan. This view of the respondent clearly highlighted 
the localized nature of knowledge in generating radical innovation, though 
the firm had to seek more collaboration for manufacturing, marketing and 
distribution in markets outside Japan. The company mostly has marketing 
and distribution agreements, investment agreements, research agreements, 
manufacturing agreements, manufacturing and marketing agreements, 
licensing agreements, technology transfer agreements and development 
agreements with its partner organizations. The company had 36 collaborative 
alliances. Primary data obtained from AnGes Inc. on the number and types of 
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Table 2: Primary data obtained from AnGes Inc on the number and type of 
alliances















1) TSD   Japan     Inc.     (MA,MDA)     
2) Amefrec Co., Ltd (RA)
3) Avontec GmbH    (MDA) 4)Mor         
ishita Jintan (RA)
5) Vical Inc,US (RA, IA)
6) Daiichi Sankyo   Co  Ltd  Japan 
(MDA).
7) BioMarin Pharmaceutical        Inc 
Japan (MDA)
8) Daiichi Pharmaceuticals     MA
9) Hokkaido System Co, MA
10) Gene design Inc, MMA
11) Immuno frontier, TTA
12) Shimadzu CorporationRA
13) NeoChemir Inc, LA
14) Gene Design Inc, DA
15)  Falco Biosystems, RA
16) Alfresa Pharma Co, RA
17) Maruishi Pharmaceutical Co. RA






3) University of 
Tokyo
4) Rush University 
Medical Center /
USA LA
5) University of 
Tokyo Hospital 
1) New Energy & Industrial Tech-
nology    Development Organiza-
tion (NEDO) Japan
2) Ministry of Economy Trade 
and Industry,    Japan
3)National Institute of Biomedi-
cal    Innovation
4) FDA (partner regulatory 
organization
5) Hosokawa Powder Technology 
Research      Institute
6) Nikko Principal Investments 
Japan Ltd
7) Pharmaceuticals and Medical 
Devices      Agency 
8) New Energy and Industrial  
Technology      Development 
Organization
9) Seikagaku Corporation
10) Goodman Co., Ltd.
11)  Meyer Pharmaceuticals
12)  Toyobo co-corporation
13)  Hosokawa Micron Corpora-
tion
14)  Transcription Factor Thera-
peutics, LA
Total alliances= 17 +5 +14 = 36
Table 2 Data obtained from AnGes Inc office by electronically.
Abbreviations: MDA (Marketing and distribution agreement), IA (Investment 
agreement), RA (Research Agreement), MA (Manufacturing Agreement), 
MMA (Manufacturing and Marketing Agreement), LA (Licensing Agreement), 
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Sample Firm 3: Polytherics Ltd. 
Formed in 2002 as a spinout company from London School of Pharmacy and 
Imperial College London, the company is competent in developing protein 
and peptide-based drugs. The business strategy of Polytherics has positioned 
its business to work in collaboration with biopharmaceutical companies to 
produce better products. Polytherics is part of the One Nucleus group and 
within this network, the company has expanded its exploratory research 
under grant-funded initiatives. On the issue of collaboration, the respondent 
was of the firm view that collaborations are the lifeblood for SMEs. Without 
collaboration, it is very difficult to obtain seed funding for research and later, 
business partners for the licensing of technology. This view of the respondent 
further validates the resource-based view for collaboration, where firms 
collaborate to gain resource interdependence. The respondent further confirms 
that the firm is involved in both exploitation and exploration of its ties with its 
partners. According to the respondent, the biotech network One Nucleus has 
provided easy access for prospective partners and has made its collaboration 
with desired partners well before the products are in their phase iii clinical 
trials. On the issue of the role of third parties in alliances, the respondent 
confirmed that most of its ties are based on mutual agreements and third parties 
have negligible roles in their ongoing and previous partnerships. According to 
the respondent, Polytherics has good diversity in its partners, ranging from 
industry and academia to governmental organizations. Most of the funding 
for Polytherics is from private and public funding organizations; this response 
is evident from the fact that private funding organizations like Imperial 
Innovation Group (Technology Development and Investment Company) and 
public funding bodies like the Biotechnology and Biological Sciences Research 
Council are involved in financing the research and product development 
activities of the firm. Polytherics mostly has licensing agreements, research 
agreements and manufacturing agreements with its partners. The company had 
alliances within and outside the One Nucleus group. While most of the partner 
knowledge organizations are within the One Nucleus Network, partner funding 
organizations are outside the network. The firm has 22 alliances. Primary data 
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1) Shantha Biotech Ltd (LA)
2) Celtic Pharma (LA)
3) Zealand Pharma (co development)
4) Isogenica Ltd (co-production)
5) Biovectra(MA)
6) DSM Biosolutions (MA)
7) Minpharm pharmaceuticals (RA)
8) Alligator Bioscience AB (RA)
9) Biocompatibles International plc
10) Avecia Ltd (MA)
11) BioVectra dcl (MA)
1) Lon-
don  School of   
Pharmacy
2) Imperial     Col-
lege  London
3) Aston  Univer-
sity
4) Hammer-
smith  Hospital 




tions  Group plc
4) Longbow  Capital
5) Regional Venture Capital 
Fund  for London.
6) Capital Fund
7) Biotechnology and Bio-
logical  Sciences Research 
Council
Number of Alliances=11 +  +4 +7= 22
Table 3 Data obtained from Polytherics  office by electronically. 
LA (Licensing Agreement), MA (Manufacturing Agreement)
Research Findings 
The key research findings are as follows: 
1)    The biotech network One Nucleus has linked the process innovations of all 
three sample firms with product innovations by providing easy access to them 
in building various types of inter-organizational alliances. 
2)    The parent network has allowed sample firms to exploit knowledge of its 
partners and helped in expanding their existing capabilities. All three sample 
firms denied the role of third party organizations in forming alliances; rather, 
they prefer more direct alliances. This finding needs more research, however, 
as the available sample responses do not convey industry views in accordance 
with the available research. 
3)  Research agreements and licensing agreements directly impact innovation 
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inside and outside the network of firms to license their patented process 
technologies.
Based on the findings of qualitative research, two hypothetical propositions are 
developed. Both are subsequently tested through quantitative methodology. 
Proposition 1: To sustain innovation, biotech companies have to form alliances 
in the form of co-development/co-promotion, licensing and other research 
agreements with different organizations within and outside the network. 
Proposition 2: The innovation output of the sample firms within the One 
Nucleus biotech network is positively impacted by the number of collaborative 
alliances. 
The proposed proposition 2 states exactly what was hypothesized earlier in 
hypothesis 2 of the introduction section; therefore, the propositions made here 
are not entirely different from the proposed hypotheses. The sample size of the 
qualitative research is three member firms of the large biotech network One 
Nucleus. This size is very small and the primary data generated on the number 
of alliances are insufficient to prove proposition 2. Therefore, the primary data 
is analyzed with the secondary data collected from the OECD biotechnology 
2009 statistics. The innovation output of the three sample biotech firms within 
the One Nucleus network is compared with the innovation output of OECD 
(US, Europe and Japanese) biotech firms. 
Quantitative Research Methodology
A quantitative research approach is used to validate some key findings of 
the qualitative research; this type of research is known as meta-analysis: 
quantitative methods of research (Wolf, 1986, p. 11). Meta-analysis means 
analysis of analyses, rigorous statistical alternatives to the casual narrative 
discussion of research studies. In this research paper, primary analysis 
generated a proposition complementing hypotheses 2 and 3, which are analyzed 
by meta-analysis of large volumes of OECD data to generate reliable results. 
In this research paper, secondary reanalysis of statistical data on independent 
variables, e.g., number of alliances and number of patent applications, is 
conducted. Innovation is a dependent variable, which depends on the number of 
alliances; thus data on patents are very helpful in measuring firms’ innovation 
and knowledge diffusion (Nelson, 2009). The number of patents is taken as a 
dependent variable that directly measures innovation output. Innovation output 
is measured in terms of the number of successful commercial patents obtained 
for each number of alliances made by the firm. Since the sample firm level data 
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data from OECD biotechnology 2009 statistics. Data is collected for the number 
of alliances and number of patent applications filed (independent variable). 
Dependent variables like patent filing application rate, patent approval rate and 
commercial patent success rate collectively measure innovation output; this 
dependent variable is measured through proposed empirical equations. The 
OECD data is a reliable source of information, as it used the UNU-MERIT 
CATI database to collect information on strategic alliances by multinational 
and domestic firms for joint research and technology transfer (Beuzekom & 
Arundel, 2009). 
Variables  
Innovation is a dependent variable that depends on the number of alliances. 
A data-based systematic layout plan is developed in which the patent 
application filing rate, patent approval rate and patent success rate are assumed 
to be dependent variables for measuring innovation output. The impact of 
independent variables, like number of alliances, on dependent variables is 
calculated through hypothetical empirical equations. 
 Independent variables: 
(1) Number of alliances 
(2) Number of patent applications filed 
Dependent variables: 
(1) Patent application filing rate or initial innovation output 
(2) Net innovation output or patent approval rate 
(3) Final innovation output or patent success rate
Innovation output is measured in terms of the patent approval rate and patent 
success rate with respect to each alliance made for research and technology 
transfer by the sample firm. Since highly reliable data on the independent 
variables are presented in OECD biotechnology statistics 2009, the collective 
innovation output for firms in OECD countries like the US, Europe and Japan 
is determined.  In the same way, the innovation output for the biotech network 
One Nucleus is determined by taking data on independent variables from 
regional OECD biotechnology 2009 statistics on South England (home of One 
Nucleus). Finally, the innovation output for sample biotech firms is determined 
by using primary data. The dependent variables were measured by hypothetical 
empirical equation. By using the empirical equation, innovation output for 
OECD members (US, Japan and Europe) is determined. The innovation output 
for One Nucleus is also determined by using OECD 2009 biotechnology 
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The comparative quantitative meta-research analysis of both primary 
and secondary data, with the help of hypothetical empirical equations, is 
used in measuring the innovation output of the sample firms. The final 
inference is drawn based on the results in proving hypotheses 2 and 3. The 
quantitative meta-analysis research design is very rigid and has limited 
flexibility to interpret the wide research picture; its focus is limited. This 
method uses different measuring techniques with different definitions 
of variables. The poorly designed studies are included with results from 
good studies; therefore, the results of the meta-analysis are uninterpretable 
(Glass et al., 1981).
The hypothetical assumption made in proposition 2, which states that 
the innovation output of the sample firm within the One Nucleus Biotech 
network is positively impacted by the number of collaborative alliances, is 
tested by a quantitative research approach. OECD biotechnology statistics 
(2009) cover alliance data from 1990 to 2006. During this period a total 
of 1,396 biotechnology alliances were included in the UNU-MERIT CATI 
database. Table 4 shows the biotech alliances by firms in the US, Europe, 
Japan and other countries.
Independent Variable: Number of Alliances 
From table 4, it is quite evident that firms in the US had 3013 (75.80%) 
of the total (3975) biotechnology alliances for research and technology 
transfer from 1990 to 2006. In the same period, firms in Europe had 2003 
(50.40%) biotechnology alliances, Japanese firms had 328 (8.25%) and 
others had 533 (13.40%) alliances for research or technology transfer.  
Table 4: Independent variable: number of alliances  
Number of  biotechnology alliances for research or technology transfer, 1990 to 2006
Year Total USA Europe Japan Others
1990 45 28 26 6 11
1991 36 33 18 3 1
1992 98 77 61 8 11
1993 124 108 53 15 9
1994 161 125 95 11 12
1995 164 127 98 15 12
1996 177 141 101 20 20
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Number of  biotechnology alliances for research or technology transfer, 1990 to 2006
1998 147 120 81 11 6
1999 190 165 83 18 18
2000 200 165 91 9 22
2001 355 274 171 17 48
2002 332 219 177 41 56
2003 368 274 178 28 52
2004 389 277 197 32 50
2005 481 358 217 54 75
2006 526 360 280 53 96
Table 4: Source: UNU-MERIT CATI database, Maastricht, the Netherlands, 
April 2009. (Accessed from OECD Biotechnology statistics 2009, page 95)
Independent Variable: Number of Patent Applications Filed 
From 1994 to 2006, the US filed 139,261 biotechnology patent applications 
under the Patent Cooperation Treaty (PCT) , whereas the EU in the same 
period filed 132,327 patent applications. Japan was ranked third, with 68,011 
PCT patent application filling (Table 5), Brazil, Russia, India and China 
(BRIC) accounted for 18,747 biotechnology patent application filings.
Table 5: Independent variable: number of patent applications filed.
Biotechnology PCT patent applications and total PCT patent applications
1994-1996                                                            2004-2006
Biotechnology Total Biotechnology Total
USA 7757 56,656 11,474 139,261
EU 3,900 54,019 7487 132,327
Japan 894 10,065 3720 68,011
BRICS 92 1,899 887 18,747
Table 5 Sources: OECD, Patent and REGPAT databases, January 2009; and 
EPO Worldwide Statistical Patent database, September 2008 (Accesed from 
OECD Biotechnology statistics 2009, page 75)
Dependent variables: Patent application filling rate or initial innovation 
output 
To determine the relationship between independent variables and dependent 
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(pApp)t / (aRTT)t = i ……………(1) 
where i is initial innovation output, which in simple terms can be defined as the 
patent filling application rate, i.e., the total number of biotechnology patent ap-
plications filed by a biotech firm for each of its single alliances with other firms/
or research organizations. pApp is total number of patent applications filed by a 
biotech firm under PCT in specific time period t.
aRTT is number of alliances for research and technology transfer in specific 
time period t. By using equation hypothetical (1), this research paper calculates 
the initial innovation output (i) for firms in the US, EU and Japan in table 6. 
Table 6:  Dependent variables: patent application filling rate or initial innova-
tion output
1994 1996 (pApp)t (aRTT)t (pApp)t/(aRTT)t=i
USA 7,757 393 7757/393=    19.73
EU 3,900 294 3,900/294=   13.26
Japan 894 46 894/46   =     19.43
2004-2006
USA 11,474 995 11474/995=  11.53
EU 7,487 694 7,487/694=   10.78
Japan 3,720 139 3720/139=    26.76
Table 6: Initial innovation output or patent filling application rate.
From Table 6, it becomes quite clear that for each single alliance made by 
the US biotech firm/research organization from period 1994-1996, it has filed 
19.73 biotech patent applications under the PCT. Single alliances had the ten-
dency to generate 19 patent applications ready for filing. In the same way, 
between 1994 and1996, each single alliance in Europe had the capacity to 
generate 13.26 patent applications ready for filing, whereas in Japan each sin-
gle alliance generated 19 patent applications for filing. The empirical results 
for innovation output from year 2004 to 2006 indicate that the patent filing 
application rate decreased to 11.53 applications for each alliance made by the 
US biotech firms or research organizations. The trend in Europe was much like 
that of the US, where a single alliance generated 10.78 patent applications. In 
Japan, though, the patent filing application rate was much higher, at 26.76.
Dependent variables: net innovation output (ni) or patent approval rate 
According to US Patent Office spokeswoman Brigid Quinn (2004), only 60 
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research conducted by the US Patent Office (2007) indicates that only 54 
percent of patent applications are approved; 46 percent are failures. In this 
research paper, the second dependent variable (approved patents) is calculated 
on the basis of 2007 US Patent Office research. The hypothetical equation (ii) 
below is used to obtain dependent variable net innovation output or approved 
patents. 
(pApp)t / (aRTT)t = i-54% ……………(ii) 
(pApp)t / (aRTT)t= ni…………………(iii)          (ie i-54%= ni)    
Therefore, net innovation output or approved patents ni (dependent variable) 
can be defined with respect to independent variables, such as patent applications 
filed and number of alliances by a firm, as follows:  
ni is net innovation output, which in simple terms can be defined as the patent 
approved rate from the total number of biotechnology patent applications filed 
by biotech firm for its each single alliance with other firms/or research orga-
nizations. pApp is the total number of patent applications filed by the biotech 
firm under PCT in a specific time period, t. 
aRTT is the number of alliances for research and technology transfer in a spe-
cific time period, t. Therefore, ni for each alliance made by the biotech firm is 
calculated by using equation (ii). Table (7) calculates ni for the US, Europe and 
Japan from 1994 to 1996 and 2004 to 2006.
Table 7: Dependent variables: net innovation output (ni) or patent approval rate
1994 1996 (pApp)t (aRTT)t (pApp)t/(aRTT)t= i-54% = ni
USA 7,757 393 19.73 -54% =               9.07
EU 3,900 294 13.26 -54%=                6.09
Japan 894 46 19.43 -54%=                8.93
2004-2006
USA 11,474 995 11.53 -54%=                5.30
EU 7,487 694 10.78 -54%=                4.95
Japan 3,720 139 26.76 -54%=                12.30
Table 7 Net innovation output or patent approval rate.
From table 7, it is quite clear that for each alliance made by US biotech firms 
from 1994 to 1996, they filed 19.73 patent applications. Only 9.07 patent 
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to each alliance was 6.09, and for Japan it was 8.93. From 2004 to2006, the 
net innovation output or patent approval rate for US biotech firms was 5.30 
with respect to each alliance made. In the same time period, the net innovation 
output or patent approval rate with respect to each alliance made by European 
and Japanese biotech firms was 4.95 and 12.30, respectively. 
Dependent variable: final innovation output or patent success rate 
Final innovation output (fi) or patent success rate measures the commercial 
success of the patent. This variable is very important for this research paper, as 
it directly measures the sustainable impact of alliances for biotech firms. Final 
innovation output (fi) or patent success rate can be defined as: 
fi is final innovation output, which in simple terms can be defined as the patent 
success rate from the total number of approved patents with respect to each 
single alliance made by a biotech firm/or research organization.
The pioneering research conducted by Harold and Bevolyn (1999) shows that 
one out of 5000 inventions has a successful product launch. The major research 
conducted by the US Patent and Trademark Office (2005) concluded that out 
of 1.5 million patents, only 3000 patents are commercially viable. Later, Mimi 
Whitefield of the Miami Herald noted that only one out of 100 patented products 
makes money. The major research studies by Kuczmarski (1991), Brown (1993) 
and Mukharjee (1998) show that only five percent of patents are commercialized; 
the remaining 95% of patents failed to earn money. The empirical equation for 
dependent variable fi (final innovation) or patent success rate is derived from 
empirical equation (i), as follows: 
(pApp)t / (aRTT)t = i…………………... (i) 
(pApp)t / (aRTT)t = i-54% …………… (ii) 
(pApp)t / (aRTT)t= ni………………… (iii)          ( ie i-54%= ni) 
(pApp)t / (aRTT)t= ni-95%..................(iv)           (ni-95%= fi) 
(pApp)t / (aRTT)t= fi…………………. (v) 
The empirical equation (v) shows the relationship between dependent variable 
(fi) and independent variables (pApp)t and (aRTT)t. 
According to empirical equation (v), the final innovation output is the patent 
success rate, derived from the number of patent applications filed by a biotech 
firm or research organization at specific time t, with respect to each alliance 
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On the basis of equation (v), table 8 calculates the patent success rate among 
biotech firms in the US, Europe and Japan from 1994 to 1996 and 2004 to 
2006. 
Table 8: Dependent variables: final innovation output or patent success rate.
1994 1996 (pApp)t (aRTT)t (pApp)t/(aRTT)t= ni-95%= fi
USA 7,757 393 9.07-95%  =           0.45
EU 3,900 294 7.16 -95% =           0.35
Japan 894 46 10.49-95% =          0.52
2004-2006
USA 11,474 995 6.22-95%  =          0.31
EU 7,487 694 5.82-95%  =           0.29
Japan 3,720 139 14.45-95% =          0.72
Table 8 Final innovation output or patent success rate.
From table 8, it is quite clear that for each alliance made by US biotech 
firms from 1994 to 1996, they filed 19.73 patent applications; only 9.07 
patent applications were approved, out of which only 0.45 patents were 
commercially successful. In Europe, the patent success rate with respect 
to each alliance was 0.35, and for Japan it was 0.52. From 2004 to 2006, 
the final innovation output or patent success rate for US biotech firms was 
0.31 with respect to each alliance made. In the same time period, the final 
innovation output or patent success rate with respect to each alliance made 
by European and Japanese biotech firms was 0.29 and 0.72, respectively. 
Innovation output for biotech network one nucleus 
In table 9, worldwide regions are ranked based on biotechnology PCT patent 
applications from 2004 to 2006. Three regions of the UK are among top 30 
regions, most notably East England (Rank 19), South-East England (Rank 
22) and London (Rank 28). These three regions are very important for this 
paper’s research because most of the member research organizations of the 
One Nucleus (BioLondon) network are in these regions. Collectively, this 
region of England accounted for 719 biotechnology PCT patent applications 
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Table 9: World Wide biotechnology region ranking on the basis of biotech-
nology PCT patent applications from 2004-2006.
Region (Territorial Level ) Country Patents total Share (%)in
1)  San Jose-San Francisco-Oakland US 1510 5.5
2)  Boston-Worcester-Manchester US 1422 5.2
3)  New York-Newark-Bridgeport US 1090 4.0
4)  Washington-Baltimore-N.Virginia US 811 3.0
5)  Tokyo JP 792 2.9
6)  San Diego-Carlsbad-San Marcos US 782 2.9
7)  Los Angeles-Long Beach-Riverside US 613 2.2
8)  Philadelphia-Camden-Vineland US 587 2.2
9)  Nordrhein-Westfalen GE 506 1.9
10)Hovedstadsregionen DK 454 1.7
TOP REGION OF ENGLAND
19)East of England
GB 262 1.0
22) South-East (England) GB 246 0.9
28) London G 201 0.7
Table 9: Sources: OECD, Patent and REGPAT databases, January 2009; and 
EPO Worldwide Statistical Patent database, September 2008 (Biotechnology 
statistics, 2009 page 71).http://www.oecd.org/dataoecd/4/23/42833898.pdf
We had OECD patent application filing data for the South-Eastern region 
of England (Table 9), where most of the biotech companies and research 
organizations are clustered together in networks like London Biotechnology 
Network (BioLondon) and Cambridge-based EBRI. Collectively this network is 
now known as One Nucleus. On the basis of the proposed empirical equations, 
this research paper calculates the innovation output for One Nucleus Network 
(this network combines both BioLondon and EBRI) for the period from 2004 to 
2006. The results are given in table 10.
Table 10:
2004-2006  (pApp)
t Networks (aRTT)t I ni  fi
East of England 262 EBRI  16 16.37 7.53 0.37
South East England 246 EBRI  18 11.16 5.13 0.25
London 201 BioLondon   8 25.12 11.55 0.57
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Table 10: calculates i initial innovation output (patent filling application rate),ni 
net innovation output (patent approval rate) and fi final innovation output (patent 
success rate for commercial activity) for South, East and South East region of 
England from 2004-2006. 
Innovation output for sample firms 
Since there are nonexistent data on the number of patent applications filed by each 
sample firm, the empirical equations developed above cannot be used to measure 
innovation output. Instead, an alternative direct approach is used, where innovation 
output is analyzed based on information available on the number of successful 
patents obtained and commercial patents obtained in generating revenues. The 
information is later validated by collecting data on the number of approved patents 
and number of commercial patents. Table 11 shows patent data for sample firms, 
the patent data collected are from the first year of the company’s operations.
Table 11: 
Year SME Networks NA AP SP
2001-2004 AERES Bio Ltd BioLondon 32 70 30
2003-2010 AnGes MG Inc BioLondon 36 31 14
2005-2010 Polytherics BioLondon 22 22 7
Table 11: Data on number of alliances (NA) for research and technology 
transfer, approved patents (AP) and successful patents (SP).
The innovation output for sample firms is calculated from 2004 to 2006. Pat-
ent approval rates and patent success rates are calculated with respect to each 
alliance made by sample firms for research, and technology transfer is shown 
in Table 11. Since clear data is available on number of approved patents and 
number of successful patents for each sample firm, patent approval rates and 
patent success rates are calculated by using equations (vi) and (vii). 
              (AP) / (aRTT)t= ni… ……..................................(vi) 
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Table 12:
SME(2004 2006) (aRTT)t       AP           SP      Ni      Fi
AERES Bio Ltd      2       18     3       9     1.5
AnGes MG Inc      3       24     2       8     0.66
Polytherics      2       19     1      9.5     0.5
Table 12: Innovation output for sample firms from 2004-2006. ni (net innova-
tion output or patent approval rate), fi (final innovation output or patent success 
rate for commercial activities).
Comparative analysis of innovation output 
The comparative analysis of innovation output in table 12 clearly shows that 
the innovation output measured in terms of patent approval rate and patent 
success rate is much higher for London-based biotech network One Nucleus. 
Except for Japan, the innovation output for One Nucleus biotech network is 
higher than the collective innovation output of firms in the US and Europe. The 
sample firm level data also pointed at improved figures in innovation output. 
All the three sample firms have higher innovation outputs than the average 
innovation output of their parent biotech network One Nucleus. 
Table 13:
2004-06 OECD  Members Network SME’s
US Europe Japan OneNuc AERES AnGes Polytherics
Ni 5.3 4.95 12.3 7.76 9 8 9.5
Fi 0.31 0.29 0.72 0.38 1.5 0.66 0.5
Table 13: showing comparative innovation output (patent approval rate, pat-
ent success rate) among OECD members, sample parent network and sample 
member firms.
From table 13, it becomes quite clear that the patent approval rate of AERES, 
AnGes and Polytherics from 2004 to 2006 was 9, 8 and 9.5 for each alliance, 
respectively. The patent approval rate, which is assumed as net innovation 
output by the researcher, is comparatively much higher than the collective net 
innovation output of firms in the US and Europe. Firms in Japan were more 
innovative than the sample firms in the same time period. The patent success 
rate or final innovation output was 1.5, 0.66 and 0.5, respectively, for sample 
firms with respect to each alliance they made for research and technology 
transfer. This rate was also quite good in comparison to final innovation rate 
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The higher innovation output for the sample firms within the One Nucleus 
network can be attributed to the fact that these sample firms had made effective 
alliances for research and technology transfer with organizations inside and 
outside the network. The number of alliances had positively impacted their 
innovation output, and this fact is clear from their higher patent approval rate 
and patent success rate with respect to each alliance they made for research 
and technology transfer (table 11). The apparent benefits for networking for 
these sample firms were also evident in part 1 of this research dissertation. The 
sample firms had very good diversity of partners, a minimal role of third party 
firms in their collaboration and above all, all three firms have good mixtures 
of product and process innovation. Table 11 also highlighted the power of 
networks in boosting the innovation output of their member firms. From table 
11 it is quite clear that from 2004 to 2006, the innovation output of the biotech 
network One Nucleus was also very much higher than the collective innovation 
output of firms in the US and Europe. The positive trend in fostering innovation 
within the network undoubtedly was transmitted to the member sample firms 
and they immensely benefitted from inter-organizational alliances within and 
outside the biotech network One Nucleus in fostering their overall innovation 
processes. 
CONCLUSION
This study explores the impact of inter-organizational networking on 
innovation. With this research, we addressed the basic broad question of 
why companies benefit from inter-organizational alliances within networks 
in fostering their innovation creation process. However, this research is 
very much a starting point in understating the impact of inter-organizational 
networking on innovation. This research used two basic methods for exploring 
the innovation output of competent sample firms, members of the large 
biotech network One Nucleus. Based on this research’s results and chosen 
methodology, a more precise research instrument can be designed. The refined 
research instrument can be included in the long list of other available research 
instruments for exploring the other aspects of inter-organizational networking. 
There are two managerial implications from this research. First, this study 
highlights the importance of inter-organizational networking for firms in 
handling and managing collaborative alliances for enhancing their overall 
innovation output. Thus, firms can be advised to analyze different aspects of 
inter-organizational networking before forming an alliance with the prospective 
partner. The analysis can be based on analyzing the reasons behind forming 
the collaboration and identifying the type of innovation the firm held at its 
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for firms to look at before forming inter-organizational collaborations include 
consideration of diversity among prospective partners. Other issues like the 
role of third party, the nature of learning and the type of alliance, whether 
licensing, co-development and research agreement, can be advised upon for 
the newly established biotech firm. Second, this research shows that innovation 
output can be measured by collecting data on patent approval rates and patent 
success rates. The empirical methodology developed in this research can be 
used to identify the positive elements in biotech networks and other partner 
firms. By using empirical equations, firms can calculate their innovation output 
with respect to each alliance they form for research and technology transfer. 
Thus, firms can make an informed decision on their selection of partners and 
can review the status of their ongoing alliances. Since this research calculates 
innovation output for sample firms from 2004 to 2006 due to the availability of 
well-defined OECD data in that time period, the current practical implications 
of this study, even for the sample firms, remain quite limited. This study can 
highlight the findings as past trends with future implications. The limitations of 
this research are two-fold: first, this research fails to develop some conceptual 
theoretical framework or innovation model that can be said to be applicable 
to the complex biotechnology industry. The reasons for this failure can be 
attributed to its small sample size. Moreover, the sample firms are in different 
stages of their developmental cycle, coincidentally having both product and 
process innovation at its core. The new insight on different aspects of inter-
organizational networking gives a rather ambiguous picture instead of a broad 
consensus on the researched issues. The broad divergence of findings at the 
firm level restricts the researcher to developing a consensus-based theoretical 
conceptual model applicable for the whole industry settings. The different 
aspects related to inter-organizational networking are much broader areas 
of research that need an individual attempt to study, which is indeed beyond 
the scope of this research. The positive thing about our research is that we 
attempted to bring those issues into the single exploratory research, which has 
partially been achieved, though much of the research questions still remain 
unanswered or were only partially answered. Second, the empirical equation 
developed to measure the innovation output of  OECD members, One Nucleus 
and sample firms only takes into account alliances that are meant for research 
and technology transfer, because these alliances are thought to boost patent 
output (OECD, 2009). The other alliances such as alliances with funding 
bodies, regulatory bodies, legal organizations, business development consulting 
firms and organizations involved in contract manufacturing, product marketing 
and promotion, are not included in data sets due to their indirect implications 
on patent activities. To include all these alliances requires a comprehensive 
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output. Future researchers should integrate the aspects of inter-organizational 
networking into a consensus-based theoretical conceptual framework or 
integrative model. The empirical design can be more efficient if other alliances 
that indirectly influence patented activities can be assimilated into more 
efficient empirical equations. The innovation output calculated in this research 
is from 2004 to 2006 because the available OECD variables are well defined in 
that time period in the OECD biotechnology 2009 report. Future researchers 
can take much more recent data sets from unconventional data sources, other 
than the OECD. Bioscan is one such website that provides recently updated 
paid data on the number of alliances and patent activities of firms, research 
organizations, partner universities and other firms throughout the world. 
This study combines processual qualitative and meta-analysis methods of 
quantitative research for comparative analysis. The findings clearly suggest 
that the biotech network One Nucleus has a positive impact on the innovation 
output of its sample member firms.
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